Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Springer

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Organic Process Research & Development|March 8, 2021
Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-FlowMichael Brown, Mohammed Aljarah, Hannah Asiki, et al.
Nature Communications|July 20, 2019
Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surfaceHaoRan Tang, Leo Leung, Grazia Saturno, et al.
Nature Communications|April 19, 2017
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surfaceHaoRan Tang, Leo Leung, Grazia Saturno, et al.
Cancer Cell|December 16, 2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaLeisl M Packer, Sareena Rana, Robert Hayward, et al.
Cancer Discovery|December 18, 2012
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanomaMaria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Cancer Discovery|February 6, 2026
Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in MelanomaMaria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Science Signaling|March 27, 2014
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signalingBerta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, et al.
Journal of Medicinal Chemistry|August 21, 2019
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor GrowthDeborah A Smithen, Leo M H Leung, Mairi Challinor, et al.
Journal of Medicinal Chemistry|May 10, 2019
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity RelationshipsLeo Leung, Dan Niculescu-Duvaz, Deborah Smithen, et al.
EMBO Molecular Medicine|June 17, 2015
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacyBryan W Miller, Jennifer P Morton, Mark Pinese, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Organic Process Research & Development|March 8, 2021
Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-FlowMichael Brown, Mohammed Aljarah, Hannah Asiki, et al.
Nature Communications|July 20, 2019
Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surfaceHaoRan Tang, Leo Leung, Grazia Saturno, et al.
Nature Communications|April 19, 2017
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surfaceHaoRan Tang, Leo Leung, Grazia Saturno, et al.
Cancer Cell|December 16, 2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaLeisl M Packer, Sareena Rana, Robert Hayward, et al.
Cancer Discovery|December 18, 2012
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanomaMaria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Cancer Discovery|February 6, 2026
Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in MelanomaMaria R Girotti, Malin Pedersen, Berta Sanchez-Laorden, et al.
Science Signaling|March 27, 2014
BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signalingBerta Sanchez-Laorden, Amaya Viros, Maria Romina Girotti, et al.
Journal of Medicinal Chemistry|August 21, 2019
2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor GrowthDeborah A Smithen, Leo M H Leung, Mairi Challinor, et al.
Journal of Medicinal Chemistry|May 10, 2019
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity RelationshipsLeo Leung, Dan Niculescu-Duvaz, Deborah Smithen, et al.
EMBO Molecular Medicine|June 17, 2015
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacyBryan W Miller, Jennifer P Morton, Mark Pinese, et al.
Pageof 3